EP1899304A1 - Derives d'acide 5-amino-1h-pyrazole-3-carboxylique en tant qu'agonistes du recepteur couple aux proteines g (rcpg) rup38 pour traiter des troubles lies au metabolisme - Google Patents

Derives d'acide 5-amino-1h-pyrazole-3-carboxylique en tant qu'agonistes du recepteur couple aux proteines g (rcpg) rup38 pour traiter des troubles lies au metabolisme

Info

Publication number
EP1899304A1
EP1899304A1 EP06770837A EP06770837A EP1899304A1 EP 1899304 A1 EP1899304 A1 EP 1899304A1 EP 06770837 A EP06770837 A EP 06770837A EP 06770837 A EP06770837 A EP 06770837A EP 1899304 A1 EP1899304 A1 EP 1899304A1
Authority
EP
European Patent Office
Prior art keywords
alkoxy
compound according
alkyl
group
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06770837A
Other languages
German (de)
English (en)
Inventor
Philip J. Skinner
Graeme Semple
Peter Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of EP1899304A1 publication Critical patent/EP1899304A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

L'invention concerne des dérivés d'acide ou d'ester carboxylique pyrazole de formule (I) ainsi que des sels pharmaceutiquement acceptables de ceux-ci présentant des propriétés pharmacologiques utiles, par exemple, comme agonistes du récepteur RCPG désignés ci-après RUP38. La présente invention porte également sur des compositions pharmaceutiques contenant des composés de l'invention, et sur des méthodes pour utiliser ces composés et ces compositions dans le traitement de troubles liés au métabolisme tels que la dyslipidémie, l'athérosclérose, l'insuffisance coronaire, la résistance à l'insuline, le diabète de type 2, le syndrome X et d'autres troubles similaires. L'invention concerne aussi l'utilisation desdits composés en combinaison avec d'autres agents actifs tels que ceux appartenant à la catégorie des inhibiteurs de l'α-glucosidase, des inhibiteurs de l'aldose réductase, des biguanides, des inhibiteurs de HMG-CoA réductase, des inhibiteurs de synthèse de squalène, des fibrates, des promoteurs du catabolisme LDL, des inhibiteurs de l'enzyme de conversion de l'angiotensine (ACE), des promoteurs de sécrétion de l'insuline et d'autres agents similaires.
EP06770837A 2005-05-23 2006-05-23 Derives d'acide 5-amino-1h-pyrazole-3-carboxylique en tant qu'agonistes du recepteur couple aux proteines g (rcpg) rup38 pour traiter des troubles lies au metabolisme Withdrawn EP1899304A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68391205P 2005-05-23 2005-05-23
PCT/US2006/019730 WO2006127595A1 (fr) 2005-05-23 2006-05-23 Derives d'acide 5-amino-1h-pyrazole-3-carboxylique en tant qu'agonistes du recepteur couple aux proteines g (rcpg) rup38 pour traiter des troubles lies au metabolisme

Publications (1)

Publication Number Publication Date
EP1899304A1 true EP1899304A1 (fr) 2008-03-19

Family

ID=37024757

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06770837A Withdrawn EP1899304A1 (fr) 2005-05-23 2006-05-23 Derives d'acide 5-amino-1h-pyrazole-3-carboxylique en tant qu'agonistes du recepteur couple aux proteines g (rcpg) rup38 pour traiter des troubles lies au metabolisme

Country Status (2)

Country Link
EP (1) EP1899304A1 (fr)
WO (1) WO2006127595A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512346A (ja) 2003-11-21 2007-05-17 アリーナ ファーマシューティカルズ， インコーポレイテッド ４−オキソ−４，５−ジヒドロ−フラン−２−カルボン酸誘導体およびその代謝関連障害の処置方法
US9278910B2 (en) 2011-05-31 2016-03-08 Receptos, Inc. GLP-1 receptor stabilizers and modulators
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
CA2851142A1 (fr) 2011-10-06 2013-04-11 Bayer Intellectual Property Gmbh Heterocyclylpyridinylpyrazole et heterocyclylpyrimidinylpyrazole utilises comme fongicides
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
EA030857B1 (ru) 2013-06-11 2018-10-31 Селджин Интернэшнл Ii Сарл Новые модуляторы рецептора glp-1
EP3230276B1 (fr) 2014-12-10 2020-09-02 Celgene International II Sarl Modulateurs du récepteur du glp-1
KR20200127999A (ko) * 2018-01-30 2020-11-11 (주)카이노스메드 유기 화합물의 염 형성
AU2022326417A1 (en) * 2021-08-10 2024-02-29 Texas Heart Institute Aminoaryl-integrin agonists compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001229727B2 (en) * 2000-02-07 2004-10-14 Bristol-Myers Squibb Co. 3-aminopyrazole inhibitors of cyclin dependent kinases
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
AU2003300014A1 (en) * 2002-10-10 2004-05-04 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006127595A1 *

Also Published As

Publication number Publication date
WO2006127595A1 (fr) 2006-11-30

Similar Documents

Publication Publication Date Title
EP1899304A1 (fr) Derives d'acide 5-amino-1h-pyrazole-3-carboxylique en tant qu'agonistes du recepteur couple aux proteines g (rcpg) rup38 pour traiter des troubles lies au metabolisme
JP5221952B2 (ja) ３−アリール−５，６−ジ置換ピリダジン類
CA2748289C (fr) Procede de preparation de composes d'amide de dihydroindene, compositions pharmaceutiques contenant les composes, et leur utilisation comme inhibiteur de proteines kinases
US7241792B2 (en) Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
JP5346292B2 (ja) ５−ｈｔ２ａセロトニン受容体に関連する障害の処置に有用な５−ｈｔ２ａセロトニン受容体の調整因子としてのピラゾール誘導体
EP1606282B1 (fr) Derives d'aryle et heteroaryle susbtitues tenant lieu de modulateurs du metabolisme du glucose et prophylaxie et traitement de troubles associes
US11560369B2 (en) Crystalline forms and processes for the preparation of cannabinoid receptor modulators
CN102417508A (zh) 作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症
US20070037836A1 (en) Mch receptor antagonists
US20060122240A1 (en) Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
KR20020062277A (ko) Ｎｏｓ 억제제로서의 ｎ-헤테로시클릭 유도체
JP2008523075A (ja) ５ｈｔ２ｃレセプター関連障害の処置に有用な５ｈｔ２ｃレセプターのモジュレーターとしてのｎ−ビアリールピペラジン誘導体およびｎ−アリールヘテロアリールピペラジン誘導体
JP2012180365A (ja) １−アリール−４−置換イソキノリン類
DE602004001134T2 (de) Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit
CN1735595A (zh) 取代的烷基酰氨基哌啶
DE60218099T2 (de) 2-Cyclohexyl-4-phenyl-1H-imidazolderivate als Liganden für den Neuropeptid Y5 Rezeptor
EP1551403B1 (fr) Derives d'acide 2h-pyrazole-3-carboxylique substitue en 5 utilises en tant qu'agents antilipotyques pour le traitement de troubles metaboliques, tels que la dyslipidemie
CN105228609A (zh) 新的转录因子调节剂
TW200845963A (en) Compounds with a combination of cannabinoid-CB1 antagonism and serotonin reuptake inhibition
US20070032537A1 (en) 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases
EP1701947B1 (fr) Derives d'acide carboxylique 4-oxo-4,5-dihydrofurane-2 et methodes pour traiter des troubles du metabolisme
TW200530193A (en) Neurokinin-3 receptor modulators: diaryl imidazole derivatives
CN117143019A (zh) 用作β2-肾上腺素受体别构拮抗剂的吡唑酰胺类衍生物
WO2014074700A1 (fr) Antagonistes du récepteur gpr119 et traitement de troubles associés à ceux-ci
TW200916442A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1receptor modulators

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WEBB, PETER

Inventor name: SEMPLE, GRAEME

Inventor name: SKINNER, PHILIP, J.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1109894

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090114

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1109894

Country of ref document: HK